| Related Knowledge Base Chapters|
| Journal Articles|
|Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community|
Middelkoop K, Bekker LG, Myer L, Johnson LF, Kloos M, Morrow C, Wood R. J Acquir Immune Defic Syndr. 2011 56:3, 263-269. Includes commentary from the UCSF Institute for Global Health.
|Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART|
Zanoni BC, Phungula T, Zanoni HM, France H, Feeney ME. AIDS. 2011, Jan 2;25(1):49-55. Includes commentary from the UCSF Institute for Global Health.
|Clinical deterioration during anti-tuberculosis treatment in Africa: Incidence, causes and risk factors|
Pepper DJ, Marais S, Wilkinson RJ, et al. BMC Infect Dis. 2010 Mar 30;10:83. Includes commentary from the UCSF Institute for Global Health.
|Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized controlled trial of immediate versus CD4+-initiated antiretroviral therapy in HIV-infected adults with a high CD4+ cell count|
Chamie G, Charlebois ED, Srikantish P, et al. Clin Infect Dis. 2010; 51: 359-62. Includes commentary from the UCSF Institute for Global Health.
|Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa|
Lawn SD, Myer L, Edwards D, et al. AIDS. 2009 Aug 24;23(13):1717-25. Includes commentary from the UCSF Institute for Global Health.
|Intensified tuberculosis case finding among HIV-infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia|
Shah S, Demissie M, Lambert L, et al. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):537-45. Includes commentary from the UCSF Institute for Global Health.
|Successful integration of tuberculosis and HIV treatment in rural South Africa: The Sizonq'oba Study|
Gandhi N, Moll A, Lalloo U, et al. JAIDS. 2009 Jan;50(1):37-43. Includes commentary from the UCSF Institute for Global Health.
|Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy|
Westreich DJ, Sanne I, Maskew M, et al. Clin Infect Dis. 2009 Jun 1;48(11):1617-23.
|Paradigm shift to address drug resistant tuberculosis in people living with HIV needed, and needed now|
Getahun H, Havlir D, Granich R, Reid A, Jaramillo E, Nunn P. Tropical Medicine & International Health. 2009 Apr;14(4):376 - 378.
|The infectiousness of tuberculosis patients coinfected with HIV|
Escombe AR, Moore DA, Gilman RH, et al. PLoS Med. 2008 Sep 30;5(9):e188.
|Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines|
Glynn J, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. AIDS. 2008;22:1859-67. Includes commentary from the UCSF Institute for Global Health.
|Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens.|
Mak A, Thomas A, Del Granado M, et al. Am J Respir Crit Care Med. 2008 Aug 1;178(3):306-12.
|Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis.|
Lew W, Pai M, Oxlade O, Martin D, et al. Ann Intern Med. 2008 Jul 15;149(2):123-34.
|Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa|
Manormoney P, Sturm AW. Clinical Infectious Diseases 2007;45:1409-1414.
|Extensively drug-resistant Mycobacterium tuberculosis: Charles Darwin would understand|
Iseman MD. Clinical Infectious Diseases 2007;45:1415-1416.
|Tuberculosis and HIV coinfection: current state of knowledge and research priorities|
Friedland G, Churchyard GJ, Nardell E. J Infect Dis. 2007 Aug 15;196 Suppl 1:S1-3.
| Guidelines and Best Practices|
|Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis|
Centers for Disease Control and Prevention, MMWR. 2009 Jan 16;58 (01); 7-10.
|Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents|
Recommendations of the CDC, the National Institutes of Health, and the Infectious Diseases Society of America; May 7, 2013.
|Guidelines for Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children|
Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Infectious Diseases Society of America (IDSA); April 10, 2009.
|Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis|
Centers for Disease Control and Prevention, December 2007.
|Improving the Diagnosis and Treatment of Smear-Negative Pulmonary and Extrapulmonary Tuberculosis among Adults and Adolescents -- Recommendations for HIV-Prevalent and Resource-Constrained Settings|
World Health Organization, November 2006. [PDF, 385K]
|International Standards for Tuberculosis Care|
Tuberculosis Coalition for Technical Assistance, WHO, March 2006. [PDF, 1.9MB]
| Policy Reports, Papers, and Briefs|
|Deadly Duo: The Synergy Between HIV/AIDS and Tuberculosis|
Center for Global Health Policy, IDSA, HIVMA, June 25, 2009. [PDF, 820K]
|Provider-Initiated HIV Testing and Counseling of TB Patients --- Livingstone District, Zambia, September 2004--December 2006 |
Centers for Disease Control and Prevention. MMWR. 2008;57(11);285-289.
|U.S. Policy Options for Strengthening Coordination between Global HIV/AIDS and TB Programs
Phillip Nieburg, Shobana Ramachandran, Kathryn Hofler. Center for Strategic and International Studies (CSIS), February 2008. [PDF, 489K]
|Global Tuberculosis Report, 2012|
World Health Organization, 2012. [PDF, 3.68MB]
|Reported HIV Status of Tuberculosis Patients --- United States, 1993--2005|
Centers for Disease Control and Prevention, MMWR 2007;56(42);1103-1106.
|Extensively Drug-Resistant Tuberculosis --- United States, 1993--2006 |
Centers for Disease Control and Prevention, MMWR 2007;56(11):250-253.
|Trends in Tuberculosis Incidence--United States, 2006|
Centers for Disease Control and Prevention, MMWR 2007;56(11):245-250.
|Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs --- Worldwide, 2000-2004 |
Centers for Disease Control and Prevention, MMWR 2006;55:301-5.
|Development of New Drugs for TB Chemotherapy - Analysis of the Current Drug Pipeline|
Médecins Sans Frontières, October 2006. [PDF, 1.2MB]
|Tuberculosis Diagnosis and Drug Sensitivity Testing - An Overview of the Current Diagnostic Pipeline|
Médecins Sans Frontières, October 2006. [PDF, 390K]
|TB/HIV Research Priorities in Resource-Limited Settings|
WHO, February 2005. [PDF, 521K]
|Fighting TB on the Front Lines: Key Findings and Recommendations on the Crucial Role Played by Front-Line Health Workers in TB Control|
Health and Development Networks, the AIDS-Care-Watch Campaign, 2005. [PDF,848K]
|Ending Neglect: The Elimination of Tuberculosis in the United States|
Institute of Medicine, Committee on the Elimination of Tuberculosis in the United States, Division of Health Promotion and Disease Prevention, June 2000.
| Presentations, Interviews, and Roundtable Discussions|
|Grand Rounds: MDR-XDR Tuberculosis|
Videos and slides of a symposium at San Francisco General Hospital about MDR-TB and XDR-TB with a focus on South Africa (Tugela Ferry outbreak) and San Francisco. UCSF, October 3, 2007.
| Research Summaries|
| Online Books and Chapters|
| Provider Education and Training|
|Tuberculosis Care with TB-HIV Comanagement: Integrated Management of Adolescent and Adult Illness (IMAI)|
Topics covered include how to diagnose TB and TB-HIV coinfection; making treatment decisions; preparing treatment cards; informing the patient and family about TB; preventive
therapy; adherence; supporting the patient during therapy; treatment monitoring; outcome evaluation; special consideration; and infection control. Items on HIV-TB coinfection
are marked in the table of contents with a red ribbon for easy reference. World Health Organization, May 2007. [PDF, 2.57 MB]
|HIV Testing and Counseling in TB Clinical Settings Tools|
Centers for Disease Control and Prevention, February 2007.
|HIV Testing and Counseling in TB Clinical Settings Tools|
Centers for Disease Control and Prevention, February 2007.
|Management of Tuberculosis in the Context of HIV/AIDS|
Pedro Cahn. Cases on the Web, International AIDS Society-USA, May 18, 2004. CME credit expired May 18, 2005.
|Management of Latent Tuberculosis Infection in Children and Adolescents: A Guide for the Primary Care Provider|
New Jersey Medical School National Tuberculosis Center, 2004. [PDF, 4.4MB]
|Guide to the Medical Management of Multidrug-Resistant Tuberculosis|
Partners in Health, Harvard Medical School, Brigham and Women's Hospital, 2003.
|Guide to the Community-Based Treatment of Multidrug-Resistant Tuberculosis: A DOTS-Plus Handbook|
Partners in Health, Harvard Medical School, Bill and Melinda Gates Foundation, 2002.
| Slide Sets|
| Program Management Materials|
|Monitoring and Evaluation Toolkit: HIV/AIDS, Tuberculosis and Malaria|
WHO, UNAIDS, The Global Fund to Fight AIDS, Tuberculosis & Malaria, USAID, U.S. Department of State, U.S. Department of Health and Human Services, CDC, UNICEF, the
World Bank, June 2004. [PDF, 2.1MB]
| Patient and Community Education|
|CDC National Center for HIV, STD and TB Prevention, Division of Tuberculosis Elimination|
Tuberculosis guidelines, surveillance reports, study modules, and more.
|CDC National Prevention Information Network: Tuberculosis Resources|
Tuberculosis training and education resource guide, FAQs, and listserv.
|Evidence-Based Tuberculosis Diagnosis|
A comprehensive resource for evidence syntheses, policies, guidelines, and research agendas on TB diagnostics
Funded by the European Commission, EuroTB is a WHO collaborating center that conducts surveillance of tuberculosis in all 51 countries of the WHO European Region.
|Francis J. Curry National Tuberculosis Center|
Creates, enhances, and disseminates state-of-the-art resources and models of excellence to control and eliminate tuberculosis nationally and internationally. Site features information on provider training, education, and distance learning; surveillance and clinical consultation; and institutional tuberculosis control.
|Global Alliance for TB Drug Development|
A nonprofit, public-private partnership whose goal is to accelerate the discovery and development of cost-effective new drugs for tuberculosis.
|The Global Fund to Fight AIDS, Tuberculosis and Malaria|
The purpose of the Fund is to attract, manage, and disburse resources through a public-private partnership that will make a sustainable and significant contribution to mitigating the impact caused by HIV/AIDS, tuberculosis, and malaria in countries in need.
|Global Health Reporting: TB|
A collection of news items, statistics, reference libraries, and other resources for health journalists, researchers, policymakers, and nongovernmental organizations. A project of the Kaiser Family Foundation. Includes Chinese, French, Hindi, Russian and Spanish versions.
|Global Health Watch|
Web site for PBS' "NewsHour With Jim Lehrer" Global Health Unit, which examines efforts to address HIV/AIDS, the increase of HIV/tuberculosis coinfections and the impact of HIV/AIDS on children.
|International Union Against Tuberculosis and Lung Disease|
A nonprofit, nongovernmental organization dedicated to the prevention and control of tuberculosis and lung disease in low- and middle-income countries.
|Johns Hopkins Center for Tuberculosis Research|
Information on epidemiology and natural history, tuberculosis drugs and treatment, and a question-and-answer forum.
|National Institute of Allergy and Infectious Diseases: Tuberculosis Research Activities|
NIAID's Division of Microbiology and Infectious Diseases is a leader in research on the basic science, prevention, and treatment of tuberculosis.
|New Jersey Medical School National Tuberculosis Center|
Education and training center that conducts state-of-the-art diagnostic, treatment, and prevention programs.
|Stop TB Initiative|
Public-private partnership coordinated by the World Health Organization and dedicated to global action to stop tuberculosis.
|World Health Organization TB Page|
Information on strategy, operations, monitoring, and evaluation of tuberculosis programs.